Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Pharma Nordic ApS

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Bankruptcy risk for industry   0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4%   Bankruptcy risk   4.1% 5.5% 2.3% 6.7% 27.5% 10.5% 5.2% 5.2%   Credit score (0-100)   50 41 64 35 1 5 16 16   Credit rating   BB BB BBB BB C B BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 -0.0 -0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   36 26 366 52 100 0 0 0   Gross profit   -11.8 -102 322 -108 -117 -5.1 0.0 0.0   EBITDA   -29.1 -120 285 -110 55.1 -5.1 0.0 0.0   EBIT   -29.1 -120 285 -110 55.1 -5.1 0.0 0.0   Pre-tax profit (PTP)   -29.1 -140.0 300.2 -109.8 55.1 -5.1 0.0 0.0   Net earnings   -29.1 -140.0 300.2 -109.8 55.1 -5.1 0.0 0.0   Pre-tax profit without non-rec. items   -29.1 -140 300 -110 55.1 -5.1 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Tangible assets total   877 1,002 1,002 1,002 0.0 0.0 0.0 0.0   Shareholders equity total   615 725 1,025 876 -18.6 -23.7 -73.7 -73.7   Interest-bearing liabilities   0.0 105 80.8 0.0 0.0 0.0 73.7 73.7   Balance sheet total (assets)   917 1,634 4,102 1,003 1,305 0.0 0.0 0.0   Net Debt   -0.2 -118 41.8 -0.8 -14.9 0.0 73.7 73.7     See the entire balance sheet 1000.0 Volume  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   36 26 366 52 100 0 0 0   Net sales growth   -14.3% -27.5% 1,303.6% -85.7% 92.1% -100.0% 0.0% 0.0%   Gross profit   -11.8 -102 322 -108 -117 -5.1 0.0 0.0   Gross profit growth   72.2% -764.8% 0.0% 0.0% -9.1% 95.6% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   917 1,634 4,102 1,003 1,305 0 0 0   Balance sheet change%   4.6% 78.2% 151.1% -75.5% 30.1% -100.0% 0.0% 0.0%   Added value   -29.1 -120.4 284.7 -109.8 55.1 -5.1 0.0 0.0   Added value %   -80.8% -461.4% 77.7% -209.9% 54.9% 0.0% 0.0% 0.0%   Investments   0 125 0 0 -1,002 0 0 0   Net sales trend   -1.0 -2.0 1.0 -1.0 1.0 -1.0 0.0 0.0   EBIT trend   -3.0 -4.0 1.0 -1.0 1.0 -1.0 0.0 0.0   1000.0 Profitability  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A EBITDA %   -80.8% -461.4% 77.7% -209.9% 54.9% 0.0% 0.0% 0.0%   EBIT %   -80.8% -461.4% 77.7% -209.9% 54.9% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   247.5% 118.5% 88.4% 102.0% -46.9% 100.0% 0.0% 0.0%   Net Earnings %   -80.8% -536.3% 81.9% -209.9% 54.9% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   -80.8% -536.3% 81.9% -209.9% 54.9% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   -80.8% -536.3% 81.9% -209.9% 54.9% 0.0% 0.0% 0.0%   ROA %   -3.2% -7.6% 10.5% -4.3% 4.7% -0.8% 0.0% 0.0%   ROI %   -4.6% -13.4% 31.0% -11.1% 12.6% 0.0% 0.0% 0.0%   ROE %   -4.6% -20.9% 34.3% -11.5% 5.1% -0.8% 0.0% 0.0%   1000.0 Solidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Equity ratio %   67.1% 44.4% 25.0% 87.4% -1.4% -100.0% -100.0% -100.0%   Relative indebtedness %   838.6% 3,481.6% 839.8% 241.9% 1,317.2% 0.0% 0.0% 0.0%   Relative net indebtedness %   838.2% 2,625.9% 829.1% 240.4% 1,302.4% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   0.5% 98.0% 14.7% 0.7% -27.1% 0.0% 0.0% 0.0%   Gearing %   0.0% 14.5% 7.9% 0.0% 0.0% 0.0% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 81.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Quick Ratio   0.0 0.2 0.0 0.0 1.0 0.0 0.0 0.0   Current Ratio   0.0 0.2 0.0 0.0 1.0 0.0 0.0 0.0   Cash and cash equivalent   0.2 223.3 38.9 0.8 14.9 0.0 0.0 0.0   1000.0 Capital use efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 4,686.2 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.4% 855.7% 10.6% 1.5% 1,298.8% 0.0% 0.0% 0.0%   Net working capital   -301.7 -685.4 -3,037.5 -125.7 -18.6 -23.7 -36.8 -36.8   Net working capital %   -838.2% -2,625.9% -829.1% -240.4% -18.5% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0